Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.
Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
Transdermal androgen appears beneficial to ageing patients with sex hormone deficiency-associated dry eye, with a recent study showing that short-term treatment relieves both symptoms and signs of the condition, as well as improves quality of life (QOL). These benefits are achieved without increasing the incidence of serious side effects.
Silent reading for as little as 30 minutes may induce measurable changes on the tear film and ocular surface in individuals at least 50 years of age, especially in those with dry eye, a study has found.
Fingerprick autologous blood (FAB) appears to be effective and safe in the treatment of severe dry eye syndrome (DES), eliminating the need for blood donation and specialist processing, as reported in a pilot study.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.